Literature DB >> 17145617

Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.

Ka Lung Wu, Meral Beksac, Jan van Droogenbroeck, Sergio Amadori, Sonja Zweegman, Pieter Sonneveld.   

Abstract

Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17145617

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  12 in total

Review 1.  Arsenic trioxide - An old drug rediscovered.

Authors:  Ashkan Emadi; Steven D Gore
Journal:  Blood Rev       Date:  2010-05-15       Impact factor: 8.250

2.  Arsenic Trioxide Combined with VCMP or VAD Chemotherapy in Patients with Refractory or Relapsed Multiple Myeloma in a Single Institution of China.

Authors:  Xiaoning Wang; Mei Zhang; Meihua Wang; Pengcheng He; Xin Liu; Limei Chen; Jieying Xi; Mengchang Wang; Jin Li; Huasheng Liu; Haitao Zhang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-01-28       Impact factor: 0.900

Review 3.  From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

Authors:  Sai-Juan Chen; Guang-Biao Zhou; Xiao-Wei Zhang; Jian-Hua Mao; Hugues de Thé; Zhu Chen
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

4.  Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

Authors:  Danka Cholujova; Zdenka Bujnakova; Erika Dutkova; Teru Hideshima; Richard W Groen; Constantine S Mitsiades; Paul G Richardson; David M Dorfman; Peter Balaz; Kenneth C Anderson; Jana Jakubikova
Journal:  Br J Haematol       Date:  2017-10-19       Impact factor: 6.998

5.  A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.

Authors:  Hongli Zhao; Guoxun Sun; Desheng Kong; Yujing Zhang; Wudan Shi; Mingming Zhao; Luojia Hong; Zhenkui Qiao
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

Review 6.  Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.

Authors:  Carmel Jacobs; Brian Hutton; Terry Ng; Risa Shorr; Mark Clemons
Journal:  Oncologist       Date:  2015-01-19

7.  Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65.

Authors:  Shihui Li; Fang Xue; Zhiyong Cheng; Xiaoyang Yang; Suyun Wang; Fengyong Geng; Ling Pan
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

8.  Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.

Authors:  Xiaoyan Qu; Juan Du; Chunyang Zhang; Weijun Fu; Hao Xi; Jianfeng Zou; Jian Hou
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

Review 9.  Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.

Authors:  Xuepeng He; Kai Yang; Peng Chen; Bing Liu; Yuan Zhang; Fang Wang; Zhi Guo; Xiaodong Liu; Jinxing Lou; Huiren Chen
Journal:  Onco Targets Ther       Date:  2014-09-10       Impact factor: 4.147

Review 10.  Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials.

Authors:  Gina Nauman; Javaughn Corey Gray; Rose Parkinson; Mark Levine; Channing J Paller
Journal:  Antioxidants (Basel)       Date:  2018-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.